Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi, which will explore its potential in a new indication not previously studied through a phase 1 study.

Gusacitinib was acquired by Formation Bio in late 2022 from Asana BioSciences as part of a broader portfolio of investigational medicines. This transaction with Sanofi ushers gusacitinib into its next stage of development, with Sanofi leveraging its global expertise in drug development and commercialization to explore its potential in new indications.

Formation Bio and Sanofi have several long-standing collaborations focused on identifying high-potential assets and co-developing AI tools that leverage shared data and technical expertise. This latest transaction builds on that collaboration, further strengthening both companies’ commitment to advancing promising therapies through innovative technology and scientific excellence.

Benjamine Liu, Co-Founder & CEO of Formation Bio, commented: “Formation Bio is redefining drug development through radical efficiency at every step. We acquire high-potential assets, move quickly to unlock value, and partner at key inflection points. We’re proud to have Sanofi as a world-class partner working together to accelerate innovation in medicine.”